EU Expands Use of XLH Therapy Crysvita to Include Older Adolescents, Adults
The European Commission (EC) has expanded the approval of Crysvita (burosumab) to treat all adolescents and adults with X-linked hypophosphatemia (XLH). The decision follows a recommendation by the…